Uvaria chamae

Uvaria chamae contains phenolics (177.6 mg/100g in root), flavonoids (165.9 mg/100g), alkaloids, tannins, saponins, and glycosides that exert DPPH free-radical scavenging, antimicrobial, and organ-protective effects through antioxidant and membrane-disrupting mechanisms. In rat models of CCl4-induced toxicity, oral stem extracts at 200–600 mg/kg body weight significantly reduced serum creatinine, urea, cardiac troponin I, LDL cholesterol, and LDH in a dose-dependent manner comparable to vitamin C at 20 mg/kg (p<0.05), though no human clinical trials have been conducted.

Origin & History

Uvaria chamae is a scrambling shrub native to tropical West and Central Africa, distributed across countries including Nigeria, Burkina Faso, Ghana, Senegal, and Cameroon, where it grows in forest margins, savanna woodlands, and secondary vegetation up to 1,500 meters elevation. It belongs to the Annonaceae family and thrives in well-drained sandy-loam soils under humid tropical conditions, often colonizing disturbed habitats and forest edges. The plant is gathered primarily from the wild for both food and medicinal use, with roots, stems, leaves, and fruits all utilized across various West African ethnobotanical traditions, particularly within Yoruba herbalism in southwestern Nigeria.

Historical & Cultural Context

Uvaria chamae holds an established place in the ethnobotanical traditions of the Yoruba people of southwestern Nigeria, where it is known by local names and incorporated into herbal formulations used by traditional healers (babalawos) for treating infections, fevers, and metabolic complaints. In Burkina Faso and other Sahelian and sub-Sahelian nations, the plant is consumed as both a food source and medicinal remedy, with its roots, leaves, and fruits integrated into daily therapeutic practices for conditions including kidney disorders, heart complaints, and skin infections. The plant is a recognized ingredient in Ruzu herbal bitters, a contemporary West African commercial herbal product blending traditional knowledge with partially modernized production, reflecting the transition of indigenous plant knowledge into semi-formalized herbal medicine markets. Documentation of specific traditional preparation recipes and dosing protocols in historical texts remains sparse, with most ethnobotanical knowledge transmitted orally across generations and compiled only recently in peer-reviewed ethnopharmacological surveys.

Health Benefits

- **Antimicrobial Activity**: Leaf fractions demonstrate minimum inhibitory concentrations (MIC) of 37 µg/mL to 1.67 mg/mL and minimum bactericidal concentrations (MBC) of 0.037–2.5 mg/mL against foodborne pathogens including Pseudomonas aeruginosa, attributed to the membrane-disrupting and oxidative-stress-inducing properties of alkaloids, tannins, and phenolic acids.
- **Antioxidant Protection**: Hydroethanolic leaf fractions show DPPH radical scavenging with IC50 values of 280 µg/mL (butanol fraction) and 379 µg/mL (ethyl acetate fraction), with activity correlating positively with total phenolic content and operating through hydrogen-atom donation and iron chelation mechanisms.
- **Nephroprotective Effects**: Aqueous and ethyl acetate stem extracts at 200–600 mg/kg significantly lowered serum urea, creatinine, uric acid, sodium, potassium, and bicarbonate in CCl4-intoxicated rats, suggesting protection of renal tubular function via attenuation of oxidative damage to kidney tissue.
- **Cardioprotective Effects**: The same stem extract doses significantly reduced cardiac troponin I (cTnI), creatine kinase (CK), lactate dehydrogenase (LDH), total cholesterol, triglycerides, and LDL in rat models, indicating mitigation of myocardial cell injury and lipid peroxidation-linked atherogenic risk.
- **Hepatoprotective Activity**: Uvaria chamae is an ingredient in Ruzu herbal bitters, a commercial West African polyherbal formulation clinically and preclinically studied for hepatoprotective, antihyperlipidemic, and antidiabetic properties, with the phenolic and flavonoid content implicated in reducing hepatic oxidative stress markers.
- **Anti-inflammatory Potential**: The rich tannin content (154.1 mg/100g in root extract) contributes to astringent and anti-inflammatory properties through inhibition of pro-inflammatory enzyme activity and protein precipitation, consistent with its traditional use in treating inflammatory conditions in Yoruba and Burkinabe ethnomedicine.
- **Antidiabetic and Antihyperlipidemic Support**: Phytochemical constituents including saponins and flavonoids are associated with glucose uptake modulation and lipid-lowering effects in preclinical contexts, forming the pharmacological basis for the plant's inclusion in traditional formulations targeting metabolic disorders across West Africa.

How It Works

The antioxidant mechanism of Uvaria chamae operates primarily through hydrogen-atom transfer and single-electron transfer pathways, with phenolic hydroxyl groups and flavonoid B-ring catechol units donating electrons to neutralize reactive oxygen species including DPPH radicals, superoxide anion, and hydroxyl radicals; this correlates quantitatively with total phenolic content across fractions. Antimicrobial activity is mediated by membrane disruption, where alkaloids intercalate into bacterial phospholipid bilayers causing leakage of intracellular contents, while tannins precipitate microbial surface proteins and chelate metal cofactors essential for bacterial enzyme function, collectively lowering MIC values to 37 µg/mL in the most active fractions. Organ-protective effects involve suppression of lipid peroxidation cascades initiated by CCl4-derived trichloromethyl radicals, with saponins and polyphenols upregulating endogenous antioxidant defenses including superoxide dismutase and catalase activity, thereby preventing oxidative damage to renal tubular epithelium and cardiomyocyte membranes as reflected by normalized serum cTnI, CK, and LDH levels. Specific receptor-binding interactions, gene expression targets, and enzyme inhibition kinetics (such as IC50 values against cyclooxygenase or xanthine oxidase) have not yet been characterized at the molecular level in peer-reviewed studies, representing a significant gap in mechanistic understanding.

Scientific Research

The scientific evidence base for Uvaria chamae consists entirely of preclinical in vitro and animal studies, with no published human clinical trials identified as of 2024, placing it at a preliminary evidence tier. Key studies include CCl4-induced toxicity models in Wistar rats (n=5 per group) examining nephro- and cardioprotective endpoints with oral stem extracts at 200–600 mg/kg, and in vitro antimicrobial assays (MIC/MBC broth microdilution) and DPPH radical scavenging assays performed on fractionated leaf hydroethanolic extracts. Phytochemical quantification studies have characterized root extract composition with reasonable analytical precision (e.g., phenolics 177.6 ± 0.75 mg/100g, flavonoids 165.9 ± 0.61 mg/100g), lending credibility to the presence of bioactive compounds, though neither standardization nor bioavailability data in humans exist. The overall body of evidence is limited by small animal group sizes, absence of dose-response modeling beyond three dose points, lack of pharmacokinetic data, and complete absence of randomized controlled trial data, meaning results cannot be extrapolated to human therapeutic use without further investigation.

Clinical Summary

No human clinical trials have investigated Uvaria chamae as a standalone intervention, and all efficacy data derive from preclinical rodent experiments and in vitro bioassays. The most structured preclinical data come from CCl4-model rat studies demonstrating dose-dependent reductions in renal function markers (urea, creatinine, uric acid) and cardiac injury markers (cTnI, CK, LDH, LDL) at 200–600 mg/kg oral stem extract, with outcomes reaching statistical significance (p<0.05) and showing comparability to the positive control vitamin C at 20 mg/kg, though effect sizes and confidence intervals were not reported. Uvaria chamae is an acknowledged constituent of Ruzu herbal bitters, which has undergone some clinical investigation for antihyperlipidemic and antidiabetic effects, but attribution of outcomes specifically to Uvaria chamae within that polyherbal mixture is not possible from available data. Confidence in translating these preclinical findings to human therapeutic recommendations is very low, and rigorous Phase I safety trials followed by efficacy RCTs are needed before any clinical claims can be substantiated.

Nutritional Profile

The root of Uvaria chamae contains crude protein (2.65 ± 0.01%) and carbohydrates (42.72 ± 0.01%) as primary macronutrients, suggesting limited direct nutritional contribution as a protein or energy source at typical medicinal doses. Phytochemical concentrations in the root are significant: phenolics (177.6 ± 0.75 mg/100g), flavonoids (165.9 ± 0.61 mg/100g), tannins (154.1 ± 1.73 mg/100g), alkaloids (107.2 ± 0.55 mg/100g), saponins (77.57 ± 1.19 mg/100g), and glycosides (10.16 ± 0.01 mg/100g). In other plant parts (leaves, stems, bark), flavonoids range 0.70–5.70 mg/100g, alkaloids 0.81–5.40 mg/100g, tannins 0.40–3.60 mg/100g, saponins 0.38–2.10 mg/100g, and phenols 0.08–0.10 mg/100g, indicating the root is the most phytochemically concentrated part. Bioavailability of these compounds in humans is unknown; the polarity-dependent fractionation data (butanol > ethyl acetate > dichloromethane > hexane for antioxidant activity) suggests that polar phenolics and flavonoids are the most bioactive fractions, consistent with generally higher intestinal absorption of hydrophilic polyphenols, though first-pass metabolism and gut microbiome transformation have not been studied for this species.

Preparation & Dosage

- **Crude Root Aqueous Decoction (Traditional)**: Roots are boiled in water and consumed as a decoction; no standardized dose exists, but traditional use in West Africa involves small volumes (approximately 50–100 mL) taken one to three times daily.
- **Hydroethanolic Leaf Extract (Research Form)**: Prepared by macerating dried leaves in 70–80% ethanol/water, then fractionating sequentially into hexane, dichloromethane, ethyl acetate, and butanol fractions; used in in vitro assays at concentrations of 37 µg/mL to 1.67 mg/mL for antimicrobial testing.
- **Aqueous and Ethyl Acetate Stem Extracts (Preclinical Oral Dosing)**: Administered to rats at 200 mg/kg, 400 mg/kg, and 600 mg/kg body weight orally; allometric scaling to a 70 kg human (using a factor of ~6.2) would suggest rough human-equivalent doses of approximately 2,258–6,774 mg/day, though this extrapolation is speculative and not validated.
- **Polyherbal Formulation (Ruzu Herbal Bitters)**: Commercially available liquid formulation containing Uvaria chamae alongside other herbs; dosing follows manufacturer or prescriber guidelines and no standardization for Uvaria chamae content is disclosed.
- **Standardization Status**: No standardized extract specifying percentage of total phenolics, flavonoids, or alkaloids is commercially available; phytochemical variability across plant parts and geographic origins precludes consistent dosing without validated standardization protocols.
- **Timing**: No clinical data exist to inform optimal timing of administration; traditional use does not specify meal-related timing.

Synergy & Pairings

Uvaria chamae is formulated alongside other West African medicinal herbs in Ruzu herbal bitters, where its phenolic and flavonoid constituents are thought to act synergistically with co-ingredients possessing antidiabetic and antihyperlipidemic properties, potentially through complementary mechanisms of insulin sensitization and lipid oxidation inhibition, though ingredient-specific attribution within the mixture has not been isolated in clinical trials. The antioxidant activity of its butanol and ethyl acetate fractions could theoretically be enhanced by combination with ascorbic acid (vitamin C) or tocopherols, which regenerate oxidized phenoxy radicals back to their active form, consistent with the use of vitamin C as a positive control in the nephroprotective rat studies. Combination with iron-rich foods or iron supplements should be approached cautiously given the tannin content, as co-administration may reduce the bioavailability of both the iron and the polyphenolic compounds through complexation.

Safety & Interactions

No formal human safety studies, toxicological assessments, or pharmacovigilance data exist for Uvaria chamae, and all available safety information derives from preclinical rat studies that reported no observable adverse effects at doses up to 600 mg/kg body weight over the study duration, which represents a very limited safety dataset. The high tannin content (154.1 mg/100g in root) raises a theoretical concern for inhibition of iron and protein absorption if consumed in large quantities or alongside iron-rich meals, and saponins at elevated doses are associated with gastrointestinal irritation and hemolytic activity in some plant species, warranting caution. Potential additive or synergistic interactions with antibiotic drugs are plausible given demonstrated antimicrobial MIC values of 37 µg/mL against Pseudomonas aeruginosa, but no clinical interaction studies have been performed; interactions with anticoagulants, antidiabetic agents, or antihypertensive medications are theoretically possible given the plant's reported physiological effects but remain uninvestigated. Uvaria chamae should be avoided during pregnancy and lactation in the absence of safety data, and individuals with kidney or liver disease should consult a healthcare provider before use, as the plant's organ-modifying bioactivity could interact unpredictably with compromised organ function or pharmaceutical treatments.